| Saturday, October 23, 2010 |
| 8:00 AM–6:00 PM |
| |
Registration |
Texas Ballroom Foyer |
| 8:00 AM–12:15 PM |
| |
Advancements in Applied Genetic Toxicology Workshop
Chairpersons:
Patricia A. Escobar, Boehringer Ingelheim Pharmaceuticals and
Krista L. Dobo, Pfizer Global R&D
Organized by the Applied Genetic Toxicology Special Interest Group
Contributing Sponsors: MolTox, Pfizer Inc., and sanofi aventis
Sponsored in part by: BioReliance Corporation |
Texas Ballroom F |
| 8:00 AM–8:10 AM |
Introduction
Patricia Escobar, Boehringer Ingelheim Pharmaceuticals |
|
| Developing a Better Understanding of Structure Activity Relationships |
| 8:10 AM–8:40 AM |
Structure Activity Relationships Associated with Genotoxic Impurities of Pharmaceuticals
Michelle Kenyon, Pfizer Inc. |
|
| 8:40 AM–9:10 AM |
Evaluating Genotoxicity SAR: Experience from Analysis of Pharmaceutical Impurities
Joel P. Bercu, Amgen Inc. |
|
| Alternative In Vitro Models for Genotoxicity Assessment |
|
| 9:10 AM–9:40 AM |
Novel In Vitro Genotoxicity Assays Using Reconstructed Human Tissues
Gladys Ouedraogo-Arras, L’Oreal |
|
| 9:40 AM–10:10 AM |
Challenges of an Automated In Vitro MN in Mammalian Cell Lines
Jing Shi, BioReliance Corporation |
|
| 10:10 AM–10:30 AM |
Break |
|
| 10:30 AM–11:00 AM |
Gamma-H2AX As a Biomarker of DNA Damage Induced by Genotoxic Agents
Asako J. Nakamura, National Cancer Institute, NIH |
|
| In Vivo Genotoxicity Testing |
| 11:00 AM–11:30 AM |
Multi-Tissue, Multi-Endpoint Assessment of Genotoxicity Using an Integrated Study Design
Maik J. Schuler, Pfizer Global R & D |
|
| 11:30 AM–12:00 NOON |
Assessment of Micronucleated Erythrocytes: From Mouse to Man
Jeffrey Bemis, Litron Laboratories |
|
| 12:00 NOON–12:15 PM |
Boxed Lunch Pick-Up |
|
| 9:00 AM–12:00 NOON |
| |
EMS Executive Board Meeting |
Sundance 1 |
| 9:30 AM–4:30 PM |
| |
Career Development Workshop
Chairpersons:
Meredith Crosby, Yale University, and
Jennifer Hobin, Federation of American Societies for Experimental Biology (FASEB)
Contributing Sponsors: Federation of American Societies for Experimental Biology (FASEB) and Research Corporation for Science Advancement |
Texas Ballroom G |
| 9:30 AM–9:50 AM |
Introduction and Overview
Meredith Crosby, Yale University |
|
| 9:50 AM–10:30 AM |
Individual Development Plans
Jennifer Hobin, Federation of American Societies for Experimental Biology (FASEB) |
|
| 10:30 AM–12:30 PM |
Roundtable Discussion 1: Research, Teaching, Administration, and Industry |
|
| 12:30 PM–1:30 PM |
Lunch on Your Own |
|
| 1:30 PM–3:30 PM |
Roundtable Discussion 2: Science Policy, Consulting, Journalism, Law, and Marketing |
|
| 3:30 PM–4:30 PM |
Available Resources and Wrap-Up |
|
| 12:15 PM–5:00 PM |
| |
Genotoxicity of Nanomaterials: Refining Strategies and Tests for Hazard Identification Workshop
Chairpersons:
Stefan J. Pfuhler, The Procter & Gamble Company and
Rosalie K. Elespuru, U.S. Food and Drug Administration
Organized by the ILSI/HESI Nanogenetox Working Group and the EMS Regulatory Task Force
Primary Sponsor: The Procter & Gamble Company
Contributing Sponsors: ILSI-HESI IVGT Project Committee and sanofi aventis |
Texas Ballroom F |
| 12:15 PM–12:30 PM |
Boxed Lunch Pick-Up |
|
| 12:30 PM–12:40 PM |
Introduction
Stefan Pfuhler, The Procter & Gamble Company |
|
| 12:40 PM–1:05 PM |
Approaches and Caveats to Investigating the Genotoxicity of Nanomaterials
Shareen H. Doak, Swansea University |
|
| 1:05 PM–1:30 PM |
Testing for Genotoxic Effects of Nanomaterials In Vitro and In Vivo
Robert Lansiedel, BASF |
|
| 1:30 PM–1:50 PM |
Developing a Coordinated International Research Effort in Nano-Genotoxicology
Tim Singer, Health Canada |
|
| 1:50 PM–2:00 PM |
Regulatory Issues Related to Genotoxicity Safety Assessment of Nanomaterials
Rosalie K. Elespuru, U.S. Food and Drug Administration |
|
| 2:00 PM–2:10 PM |
The Principal Approaches to Genotoxic Hazard Assessment of Nanomaterials in Japan
Masamitsu Honma, National Institute of Health Sciences, Tokyo |
|
| 2:15 PM–3:30 PM |
Break-Out Groups:
|
|
| |
Group 1: Standard In Vitro Assays: Assessment/Strategy Development
Leaders:
Marilyn J. Aardema, Marilyn Aardema Consulting LLC and
Shareen H. Doak, Swansea University |
Sundance 1 |
| |
Group 2: Standard In Vivo Assays: Assessment/Strategy Development
Leaders:
E. Maria Donner, Dupont Haskell Laboratory and
Mugimane Manjanatha, National Center for Toxicological Research, U.S. FDA |
Sundance 2 |
| |
Group 3: Integration of New Technologies: Which Ones and When are They Needed?
Leaders:
Micheline Kirsch-Volders, Vrije Universiteit Brussel and Masamitsu Honma, NIHS Japan |
Texas Ballroom F |
| 3:30 PM–3:45 PM |
Break |
|
| 3:45 PM–5:00 PM |
Break-Out Group Summaries, General Discussion and Consensus Development |
Texas Ballroom F |
| 12:30 PM–4:00 PM |
| |
EMS Council Meeting |
Stockyards 1 |
| 4:30 PM–6:30 PM |
| |
Welcome Reception and Student/New Investigator Poster Session
Sponsored in part by: Genetic Toxicology Association |
Texas Ballroom E |
General Information